JP2013508454A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013508454A5 JP2013508454A5 JP2012536876A JP2012536876A JP2013508454A5 JP 2013508454 A5 JP2013508454 A5 JP 2013508454A5 JP 2012536876 A JP2012536876 A JP 2012536876A JP 2012536876 A JP2012536876 A JP 2012536876A JP 2013508454 A5 JP2013508454 A5 JP 2013508454A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- pharmaceutically acceptable
- adrenergic receptor
- receptor agonist
- erythema
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010015150 Erythema Diseases 0.000 claims 22
- 230000001154 acute effect Effects 0.000 claims 21
- 231100000321 erythema Toxicity 0.000 claims 21
- 238000011282 treatment Methods 0.000 claims 20
- 150000003839 salts Chemical class 0.000 claims 14
- 239000000126 substance Substances 0.000 claims 9
- 239000000695 adrenergic alpha-agonist Substances 0.000 claims 7
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 claims 5
- 201000004624 Dermatitis Diseases 0.000 claims 5
- 208000006877 Insect Bites and Stings Diseases 0.000 claims 5
- 239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 claims 5
- 229960003679 brimonidine Drugs 0.000 claims 5
- 206010061218 Inflammation Diseases 0.000 claims 4
- 239000000533 adrenergic alpha-1 receptor agonist Substances 0.000 claims 4
- 230000004054 inflammatory process Effects 0.000 claims 4
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 3
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 2
- HUCJFAOMUPXHDK-UHFFFAOYSA-N Xylometazoline Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCCN1 HUCJFAOMUPXHDK-UHFFFAOYSA-N 0.000 claims 2
- 229960001528 oxymetazoline Drugs 0.000 claims 2
- 238000011200 topical administration Methods 0.000 claims 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims 1
- 229930182837 (R)-adrenaline Natural products 0.000 claims 1
- IWEGDQUCWQFKHS-UHFFFAOYSA-N 1-(1,3-dioxolan-2-ylmethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CN(CC2OCCO2)N=C1 IWEGDQUCWQFKHS-UHFFFAOYSA-N 0.000 claims 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 claims 1
- 208000035874 Excoriation Diseases 0.000 claims 1
- GMPKIPWJBDOURN-UHFFFAOYSA-N Methoxyamine Chemical compound CON GMPKIPWJBDOURN-UHFFFAOYSA-N 0.000 claims 1
- 206010042496 Sunburn Diseases 0.000 claims 1
- 238000005299 abrasion Methods 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 229960001724 brimonidine tartrate Drugs 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960005139 epinephrine Drugs 0.000 claims 1
- 238000004299 exfoliation Methods 0.000 claims 1
- 229960005016 naphazoline Drugs 0.000 claims 1
- 229960002748 norepinephrine Drugs 0.000 claims 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 229960001802 phenylephrine Drugs 0.000 claims 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 claims 1
- 238000002428 photodynamic therapy Methods 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 150000004492 retinoid derivatives Chemical class 0.000 claims 1
- -1 tetrahydrozaline Chemical compound 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 229960000833 xylometazoline Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25480509P | 2009-10-26 | 2009-10-26 | |
| US61/254,805 | 2009-10-26 | ||
| PCT/US2010/053198 WO2011053487A1 (en) | 2009-10-26 | 2010-10-19 | Methods of treating or preventing acute erythema |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013508454A JP2013508454A (ja) | 2013-03-07 |
| JP2013508454A5 true JP2013508454A5 (enExample) | 2013-12-26 |
Family
ID=43922456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012536876A Pending JP2013508454A (ja) | 2009-10-26 | 2010-10-19 | 急性紅斑の治療又は予防法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20110224216A1 (enExample) |
| EP (1) | EP2493309A4 (enExample) |
| JP (1) | JP2013508454A (enExample) |
| KR (1) | KR20120125230A (enExample) |
| CN (1) | CN102711471A (enExample) |
| AU (1) | AU2010313643B2 (enExample) |
| BR (1) | BR112012009891A2 (enExample) |
| CA (1) | CA2779063A1 (enExample) |
| MX (1) | MX2012004890A (enExample) |
| NZ (1) | NZ600125A (enExample) |
| RU (1) | RU2012122983A (enExample) |
| WO (1) | WO2011053487A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8410102B2 (en) | 2003-05-27 | 2013-04-02 | Galderma Laboratories Inc. | Methods and compositions for treating or preventing erythema |
| US7812049B2 (en) * | 2004-01-22 | 2010-10-12 | Vicept Therapeutics, Inc. | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
| US20110172180A1 (en) | 2010-01-13 | 2011-07-14 | Allergan Industrie. Sas | Heat stable hyaluronic acid compositions for dermatological use |
| US9114188B2 (en) | 2010-01-13 | 2015-08-25 | Allergan, Industrie, S.A.S. | Stable hydrogel compositions including additives |
| RU2535008C2 (ru) | 2010-03-26 | 2014-12-10 | Галдерма Ресерч Энд Девелопмент | Улучшенные способы и композиции для безопасного и эффективного лечения телеангиэктазии |
| MX2012010824A (es) | 2010-03-26 | 2012-10-10 | Galderma Res & Dev | Metodos y composiciones mejoradas para tratamiento seguro y efectivo del eritema. |
| RU2587041C2 (ru) | 2010-06-30 | 2016-06-10 | Галдерма Ресерч Энд Девелопмент | Способ предотвращения или лечения опухоли кожи |
| AU2011273509A1 (en) | 2010-06-30 | 2013-06-13 | Galderma Research & Development | Use of alpha-adrenergic receptor agonist for preventing or treating skin tumor |
| SG189896A1 (en) | 2010-10-21 | 2013-06-28 | Galderma Sa | Brimonidine gel compositions and methods of use |
| US8053427B1 (en) * | 2010-10-21 | 2011-11-08 | Galderma R&D SNC | Brimonidine gel composition |
| AU2012217858A1 (en) | 2011-02-15 | 2013-09-05 | Allergan, Inc. | Pharmaceutical cream compositions of oxymetazoline for treating symptoms of rosacea |
| US9283217B2 (en) | 2011-11-10 | 2016-03-15 | Allergan, Inc. | Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions |
| UA109359C2 (xx) * | 2011-11-10 | 2015-08-10 | Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном | |
| AU2014262960A1 (en) * | 2013-05-06 | 2015-11-26 | Allergan, Inc. | Alpha adrenergic agonists for the treatment of tissue trauma |
| EP2962689B1 (en) * | 2014-06-30 | 2018-04-11 | Galderma S.A. | Method of treating flushing associated with carcinoid tumors and carcinoid syndrome |
| CN106361733A (zh) * | 2015-07-22 | 2017-02-01 | 刘里远 | 外用经穴激动剂 |
| EP3434271B1 (en) * | 2016-03-22 | 2020-08-26 | Doris Maria Hexsel | Use of pharmaceutical composition for the treatment of poikiloderma of civatte |
| FR3119986B1 (fr) * | 2021-02-19 | 2024-02-16 | Tarian Pharma | Composition émulsion eau dans huile et ses utilisations dans la prévention et/ou le traitement des dommages cutanés causés par les rayonnements |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6911196B2 (en) * | 2002-07-31 | 2005-06-28 | Samir I. Hamtini | Topical medicament for treating nappy rash |
| US7439241B2 (en) * | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
| US8410102B2 (en) * | 2003-05-27 | 2013-04-02 | Galderma Laboratories Inc. | Methods and compositions for treating or preventing erythema |
| US20050020600A1 (en) * | 2003-07-23 | 2005-01-27 | Scherer Warren J. | Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists |
| US7812049B2 (en) * | 2004-01-22 | 2010-10-12 | Vicept Therapeutics, Inc. | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
| US20050226899A1 (en) * | 2004-04-08 | 2005-10-13 | Mauro Castiglioni | Cosmetic mask composition |
| CA2567401C (en) * | 2004-05-25 | 2013-11-12 | Sansrosa Pharmaceutical Development, Inc. | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders |
| US7709014B2 (en) * | 2005-10-17 | 2010-05-04 | Yu Ruey J | Hydroxy-oligocarboxylic esters: effects on nerve and use for cutaneous and mucocutaneous organs or sites |
| US20090061020A1 (en) * | 2007-08-31 | 2009-03-05 | Theobald Klaus P | Brimonidine Compositions for Treating Erythema |
| MX2012010824A (es) * | 2010-03-26 | 2012-10-10 | Galderma Res & Dev | Metodos y composiciones mejoradas para tratamiento seguro y efectivo del eritema. |
| US20120101104A1 (en) * | 2010-10-21 | 2012-04-26 | Galderma S.A. | Topical gel compositions and methods of use |
| US8053427B1 (en) * | 2010-10-21 | 2011-11-08 | Galderma R&D SNC | Brimonidine gel composition |
-
2010
- 2010-10-19 EP EP20100827329 patent/EP2493309A4/en not_active Withdrawn
- 2010-10-19 RU RU2012122983/15A patent/RU2012122983A/ru unknown
- 2010-10-19 BR BR112012009891A patent/BR112012009891A2/pt active Search and Examination
- 2010-10-19 MX MX2012004890A patent/MX2012004890A/es unknown
- 2010-10-19 AU AU2010313643A patent/AU2010313643B2/en not_active Ceased
- 2010-10-19 KR KR1020127013737A patent/KR20120125230A/ko not_active Ceased
- 2010-10-19 CN CN2010800485638A patent/CN102711471A/zh active Pending
- 2010-10-19 CA CA2779063A patent/CA2779063A1/en not_active Abandoned
- 2010-10-19 JP JP2012536876A patent/JP2013508454A/ja active Pending
- 2010-10-19 NZ NZ60012510A patent/NZ600125A/en not_active IP Right Cessation
- 2010-10-19 WO PCT/US2010/053198 patent/WO2011053487A1/en not_active Ceased
- 2010-10-19 US US12/907,543 patent/US20110224216A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013508454A5 (enExample) | ||
| RU2012122983A (ru) | Способ лечения и профилактики острой эритемы | |
| Ibbotson et al. | Ambulatory photodynamic therapy using low irradiance inorganic light‐emitting diodes for the treatment of non‐melanoma skin cancer: an open study | |
| Andreu et al. | Current progress and challenges of nanoparticle-based therapeutics in pain management | |
| CA2780586C (en) | Combination therapy for treating or preventing an inflammatory skin disorder | |
| Ma et al. | Prospective study of topical 5‐aminolevulinic acid photodynamic therapy for the treatment of severe adolescent acne in Chinese patients | |
| US20120076738A1 (en) | Combination treatment for dermatological conditions | |
| WO2009053741A3 (en) | Novel formulation | |
| ECSP099348A (es) | Composición farmacéutica de liberación modificada de un músculo relajante y un aine | |
| Tong et al. | Brimonidine tartrate for the treatment of facial flushing and erythema in rosacea | |
| Holliday et al. | Methotrexate: role of treatment in skin disease | |
| US20170095466A1 (en) | Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions | |
| JP2014530847A5 (enExample) | ||
| CN105188691A (zh) | 用于治疗组织创伤的α-肾上腺素能激动剂 | |
| RU2014119919A (ru) | Способ лечения капиллярных гемангиом | |
| US10201535B2 (en) | Pharmaceutical compositions comprising 7-(1H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions | |
| Nilforoushzadeh et al. | A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omeprazole in the treatment of cutaneous leishmaniasis. | |
| US20110294894A1 (en) | Pharmaceutical Composition for the Treatment of Solar Urticaria | |
| Trickett et al. | Managing rosacea | |
| Benoit et al. | Psoriasis from a prosthesis: unusual Koebner phenomenon in a girl with autoamputation of the leg | |
| US20140170231A1 (en) | Pain relief compositions and methods | |
| TR201815794A2 (tr) | Sedef hastaliğini tedavi̇ edi̇ci̇ bi̇tki̇sel yağ bazli 1000 ml koyu kahverengi̇ cam şi̇şede sivi sprey | |
| HK1177102A (en) | Methods of treating or preventing acute erythema | |
| Elewshi et al. | Family Practice News. 43.14 (Sept. 1, 2013): pS11. |